Medivir AB

Equities

MVIR B

SE0020181014

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:31 2024-04-26 am EDT			5-day change	1st Jan Change
3.24 ^SEK	+6.23%		+21.35%	+13.68%

Apr. 25	Medivir Gets Two US FDA Designations for MIV-711	MT
Mar. 21	Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	CI

Medivir AB Appoints Nomination Committee

October 23, 2023 at 02:40 am EDT

Medivir AB announced that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2024. According to an AGM resolution, the Nomination Committee 2023-2024 should consist of representatives of at least the three largest shareholders at the end of the third quarter of 2023 and the Chairman of the Board. Work on composing the Nomination Committee is now completed, and this year?s Nomination Committee consists of: Karl Tobieson, appointed by Linc AB; Richard Torgerson, appointed by Nordea Investment Funds; Anders Hallberg, appointed by HealthInvest Partners; Uli Hacksell, Chairman of the Board, Medivir AB.

The 2024 Annual General Meeting of Medivir will be held on May 7, 2024.

Latest news about Medivir AB

Medivir Gets Two US FDA Designations for MIV-711	Apr. 25	MT
Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	Mar. 20	CI
Medivir Presents Data That Strengthens the Fostrox/Lenvima Combination in Primary Liver Cancer At Easl Liver Cancer Summit	Feb. 22	CI
Transcript : Medivir AB, Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Medivir AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Medivir AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Transcript : Medivir AB - Special Call	Jan. 23
Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress	Jan. 18	CI
Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer	Jan. 17	CI
Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers	Dec. 19	CI
Medivir, Lonza Sign Manufacturing Deal for Fostrox	Dec. 13	MT
Medivir AB Agrees with Lonza to Manufacture a Fostrox GMP Campaign, to Be Tested in 2L HCC with Intent to Commercialize Via Accelerated Approval	Dec. 13	CI
Medivir to Discuss Birinapant Future Following Partner's Strategic Reprioritization	Dec. 06	MT
Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC	Nov. 27	CI
Medivir AB to Present Clinical Data at ASCO-GI with Fostrox + Lenvima in HCC and Shares Positive Response from Type D Meeting with FDA	Nov. 13	CI
Transcript : Medivir AB - Special Call	Nov. 08
Medivir Shares Fall Amid SEK148 Million Rights Issue at Discounted Price	Nov. 08	MT
Transcript : Medivir AB, Nine Months 2023 Earnings Call, Oct 27, 2023	23-10-27
Medivir AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-27	CI
Medivir AB to Report New and Updated Data from Ongoing Phase 2a HCC Study as Part of Its Third Quarter Report on Friday	23-10-25	CI
Medivir AB Appoints Nomination Committee	23-10-23	CI
Medivir AB Announces Resignation of Anette Lindqvist as Director	23-10-20	CI
Medivir Reports 'Very Promising' Results from Mid-stage Study for Liver Cancer Combo	23-10-05	MT
Medivir Says Phase 2a Study of Fostrox With Lenvima Has 17% Overall Response Rate, 72% Disease Control Rate	23-10-05	MT
Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle	23-10-05	CI

Chart Medivir AB

Duration

Period

More charts

Company Profile

Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Q1 2024 Earnings Call

More about the company

Income Statement Evolution

More financial data

Ratings for Medivir AB

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.24 SEK

Average target price

20.55 SEK

Spread / Average Target

+534.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDIVIR AB	+13.68%	33.11M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs